KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Twist Bioscience (TWST) Cash & Equivalents (2018 - 2025)

Twist Bioscience (TWST) has disclosed Cash & Equivalents for 6 consecutive years, with $315.2 million as the latest value for Q1 2023.

  • On a quarterly basis, Cash & Equivalents fell 22.68% to $315.2 million in Q1 2023 year-over-year; TTM through Mar 2023 was $315.2 million, a 22.68% decrease, with the full-year FY2022 number at $378.7 million, down 14.42% from a year prior.
  • Cash & Equivalents was $315.2 million for Q1 2023 at Twist Bioscience, roughly flat from $316.7 million in the prior quarter.
  • In the past five years, Cash & Equivalents ranged from a high of $475.3 million in Q2 2021 to a low of $46.7 million in Q3 2019.
  • A 5-year average of $292.8 million and a median of $332.7 million in 2020 define the central range for Cash & Equivalents.
  • Peak YoY movement for Cash & Equivalents: crashed 42.13% in 2019, then skyrocketed 372.39% in 2021.
  • Twist Bioscience's Cash & Equivalents stood at $46.7 million in 2019, then surged by 646.31% to $348.8 million in 2020, then rose by 26.86% to $442.5 million in 2021, then fell by 28.43% to $316.7 million in 2022, then dropped by 0.47% to $315.2 million in 2023.
  • Per Business Quant, the three most recent readings for TWST's Cash & Equivalents are $315.2 million (Q1 2023), $316.7 million (Q4 2022), and $378.7 million (Q3 2022).